Overexpression of ROD1 Inhibits Invasion of Breast Cancer Cells by Suppressing the Translocation of β-catenin into the Nucleus

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Jul 18

PMID 30013660

Citations 5

Authors

Ya Zhou

Hanqing Zou

Enhao Wu

Lei Huang

Rui Yin

Yuxin Mei

Xun Zhu

Affiliations

Soon will be listed here.

Abstract

The incidence of breast cancer is increasing throughout the world. Although significant progress has been made in diagnostic techniques and targeted therapies, the prognosis of breast cancer remains poor. Regulator of differentiation 1 (ROD1) may inhibit the development of several types of cancer. However, the role of ROD1 in breast cancer cells remains unknown. In the present study, western blot analysis and reverse transcription-quantitative polymerase chain reaction revealed that expression of ROD1 was significantly reduced in breast cancer cells. Overexpression of ROD1 reduced the proliferation rate, demonstrated using a Cell Counting Kit-8 assay. Additionally, the overexpression of ROD1 decreased the invasiveness of breast cancer cells, indicating that ROD1 may serve as a tumor suppressor. Additionally, the data suggested that ROD1 significantly suppressed the activity of Wnt luciferase reporter (TOP Flash) in MDA-MB-231 cells. Furthermore, it was demonstrated that ROD1 may interact with β-catenin by using co-immunoprecipitation, resulting in suppression of β-catenin migration into the nucleus. Notably, ROD1 demonstrated its anticancer effect by decreasing β-catenin (Y333) phosphorylation in a nude mouse xenograft model. Overexpression of ROD1 may downregulate Ki67 protein levels, as determined by immunohistochemistry. These results indicated that ROD1 may be used as a therapeutic target in patients with breast cancer.

Citing Articles

Polypyrimidine Tract Binding Protein: A Universal Player in Cancer Development.

Gonzalez E, Flatt T, Farooqi M, Johnson L, Ahmed A Curr Mol Med. 2023; 24(12):1450-1460.

PMID: 37877563 DOI: 10.2174/0115665240251370231017053236.

Podocyte specific deletion of PKM2 ameliorates LPS-induced podocyte injury through beta-catenin.

AlQuraishi M, Chahed S, Alani D, Puckett D, Dowker P, Hubbard K Cell Commun Signal. 2022; 20(1):76.

PMID: 35637461 PMC: 9150347. DOI: 10.1186/s12964-022-00884-6.

New Insights Into PTBP3 in Human Cancers: Immune Cell Infiltration, TMB, MSI, PDCD1 and m6A Markers.

Fang Z, Li P, Li H, Chong W, Li L, Shang L Front Pharmacol. 2022; 13:811338.

PMID: 35359851 PMC: 8960631. DOI: 10.3389/fphar.2022.811338.

Constructing and validating a diagnostic nomogram for multiple sclerosis via bioinformatic analysis.

Li H, Sun Y, Chen R 3 Biotech. 2021; 11(3):127.

PMID: 33680693 PMC: 7886954. DOI: 10.1007/s13205-021-02675-1.

PTBP3 promotes migration of non-small cell lung cancer through regulating E-cadherin in EMT signaling pathway.

Wu Q, Zhang B, Li B, Cao X, Chen X, Xue Q Cancer Cell Int. 2020; 20:172.

PMID: 32477006 PMC: 7236532. DOI: 10.1186/s12935-020-01240-9.

References

Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D . Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer. 2004; 101(6):1345-56. DOI: 10.1002/cncr.20518. View

Brazao T, Demmers J, van Ijcken W, Strouboulis J, Fornerod M, Romao L . A new function of ROD1 in nonsense-mediated mRNA decay. FEBS Lett. 2012; 586(8):1101-10. DOI: 10.1016/j.febslet.2012.03.015. View

Fiebig H, Berger D, Winterhalter B, Plowman J . In vitro and in vivo evaluation of US-NCI compounds in human tumor xenografts. Cancer Treat Rev. 1990; 17(2-3):109-17. DOI: 10.1016/0305-7372(90)90034-d. View

Maniatis T, Tasic B . Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature. 2002; 418(6894):236-43. DOI: 10.1038/418236a. View

Yang F, Zeng Q, Yu G, Li S, Wang C . Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. Cell Signal. 2005; 18(5):679-87. DOI: 10.1016/j.cellsig.2005.06.015. View

Behrens J . Control of beta-catenin signaling in tumor development. Ann N Y Acad Sci. 2000; 910:21-33; discussion 33-5. DOI: 10.1111/j.1749-6632.2000.tb06698.x. View

Chen B, Zhao A, Shao J, Mu X, Jiang L, Liu J . The effects of PTBP3 silencing on the proliferation and differentiation of MKN45 human gastric cancer cells. Life Sci. 2014; 114(1):29-35. DOI: 10.1016/j.lfs.2014.07.038. View

Luo J, Deng Z, Luo X, Tang N, Song W, Chen J . A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc. 2007; 2(5):1236-47. DOI: 10.1038/nprot.2007.135. View

Lindvall C, Evans N, Zylstra C, Li Y, Alexander C, Williams B . The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis. J Biol Chem. 2006; 281(46):35081-7. DOI: 10.1074/jbc.M607571200. View

10.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

11.

Holland J, Klaus A, Garratt A, Birchmeier W . Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol. 2013; 25(2):254-64. DOI: 10.1016/j.ceb.2013.01.004. View

12.

Gaspar C, Fodde R . APC dosage effects in tumorigenesis and stem cell differentiation. Int J Dev Biol. 2004; 48(5-6):377-86. DOI: 10.1387/ijdb.041807cg. View

13.

Amado N, Fonseca B, Cerqueira D, Moura Neto V, Abreu J . Flavonoids: potential Wnt/beta-catenin signaling modulators in cancer. Life Sci. 2011; 89(15-16):545-54. DOI: 10.1016/j.lfs.2011.05.003. View

14.

Sun B, Zhang S, Zhang D, Liu Y, Li Y, Rong Z . Clusterin is associated with spontaneous breast cancer in TA2 mice. FEBS Lett. 2007; 581(17):3277-82. DOI: 10.1016/j.febslet.2007.06.021. View

15.

Rosano L, Cianfrocca R, Spinella F, Di Castro V, Nicotra M, Lucidi A . Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res. 2011; 17(8):2350-60. DOI: 10.1158/1078-0432.CCR-10-2325. View

16.

DeSantis C, Ma J, Bryan L, Jemal A . Breast cancer statistics, 2013. CA Cancer J Clin. 2013; 64(1):52-62. DOI: 10.3322/caac.21203. View

17.

Lu F, Sun Y, Wei C, Thisse C, Thisse B . Tissue-specific derepression of TCF/LEF controls the activity of the Wnt/β-catenin pathway. Nat Commun. 2014; 5:5368. DOI: 10.1038/ncomms6368. View

18.

Lin S, Xia W, Wang J, Kwong K, Spohn B, Wen Y . Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A. 2000; 97(8):4262-6. PMC: 18221. DOI: 10.1073/pnas.060025397. View

19.

Zhang D, Fei F, Li S, Zhao Y, Yang Z, Qu J . The role of β-catenin in the initiation and metastasis of TA2 mice spontaneous breast cancer. J Cancer. 2017; 8(11):2114-2123. PMC: 5559974. DOI: 10.7150/jca.19723. View

20.

Lv K, Guo Y, Zhang Y, Wang K, Li K, Zhu Y . Transient inhibition of foot-and-mouth disease virus replication by siRNAs silencing VP1 protein coding region. Res Vet Sci. 2008; 86(3):443-52. PMC: 7127796. DOI: 10.1016/j.rvsc.2008.10.011. View